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Objective To investigate the correlation between serum thyroid-stimulating hormone (TSH) concentration and
nodule nature in pediatric patients with thyroid nodules, with the aim of identifying a marker able to differentiate
benign and malignant nodules.
Study design This was a retrospective analysis of serum TSH concentrations in a multicentric case series of 125
pediatric patients with benign and malignant thyroid nodules.
Results Of the 125 patients, 99 had benign thyroid nodules and 26 had differentiated thyroid cancer (24 papillary
and 2 follicular). Final diagnosis was based on surgery in 57 cases and on a benign cytology plus clinical follow-up in
68cases. SerumTSHconcentrationwassignificantly higher inpatientswith thyroid cancer comparedwith thosewith
benign nodules (3.23  1.59 mU/L vs 1.64  0.99 mU/L; P < .001). Binary logistic regression analysis revealed that
serumTSHwas the sole predictor ofmalignancy (P < .001). Dividing the patient cohort into 5 groups based on serum
TSH quintiles (TSH cutoffs 0.40, 1.00, 1.50, 1.80, and 2.80 mU/L), we observed that cancer prevalence increased in
parallel with serum TSH (P < .001), with respective rates of 0%, 4%, 16%, 32%, and 52% in the 5 quintile groups.
Conclusion Becausecaseswithmalignantnodulesaremost likely seen in theuppernormal serumTSHrange (ie, >2.8
mU/L), serumTSHconcentrationcan serveasapredictor of thyroid cancer in pediatric patientswith thyroid nodules and
can inform the decision of when to submit patients to further investigation by cytology. (J Pediatr 2013;163:1465-70).
T
hyroid cell proliferation depends on thyrotropin (thyroid-stimulating hormone [TSH]), which is the main factor acting
on thyroid tissue. Evidence suggests that TSH signaling may be implicated in differentiated thyroid cancer, in which ma-
lignant cells usually express TSH receptor.1 Overactivation and hyperfunction of the TSH receptor has been observed in
differentiated thyroid cancer, whereas it is most often silenced in the undifferentiated form.2 Moreover, in animal models,
induced TSH elevation leads to thyroid hyperstimulation, resulting in hyperplasia and increased cancer development rate.3-5
Clinical observations point to a correlation between thyroid cancer and serum TSH concentration. Several previous inves-
tigations of adults with thyroid nodules have shown that a TSH concentration in the upper end of the reference range is corre-
lated with an increased likelihood of thyroid cancer; serum TSH concentrations are higher in patients with differentiated
thyroid cancer compared with those with benign thyroid nodules.6 In addition, patients with nodular goiter have lower serum
TSH concentrations and a lower frequency of papillary thyroid cancer when treated with levothyroxine.7 Moreover, levothyr-
oxine administration at dosages that induce serum TSH suppression have been linked to a reduced risk of thyroid cancer recur-
rence and increased survival.8 Finally, levothyroxine treatment may interfere with growth and formation of nodules.8-12
Two systematic reviews examining the association between serum TSH concentrations and differentiated thyroid cancer in
adults have been published.13,14 Thyroid nodules are very rare in the pediatric population, with an estimated prevalence of onlyFrom the 1Division of Pediatric Endocrinology,
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children.17 Furthermore, pediatric thyroid cancer appears to be unique, differing
from the adult form in terms of epidemiology and natural history. Thyroid nod-
ules are more often malignant in children than in adults (20%-25% of cases vs
5%-10%),18-22 and pediatric thyroid cancer is almost invariably well differenti-
ated and thus likely to be TSH-dependent.
In the present study, we investigated the correlation between serum TSH con-
centration and cytotype/histotype of thyroid nodules in children, with the aim of
identifying a biochemical marker of malignancy for use in clinical practice.University of Modena and Reggio Emilia, Modena and
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In this multicenter retrospective study of 125 patients with
thyroid nodules diagnosed in childhood or adolescence,
data were collected from a series of consecutive cases diag-
nosed and followed-up between 2006 and 2012 in 9 centers
in the Study Group for Thyroid Diseases of the Italian
Society for Pediatric Endocrinology and Diabetology. All
of the clinicians involved were pediatric endocrinologists
working in clinics dedicated to the diagnosis and treatment
of thyroid cancer, thyroid nodules, and other complex thy-
roid disorders. Institutional Review Board approval and
patiental informed consent were not required by the insti-
tutions for retrospective studies involving the anonymous
review of medical records of patients followed at those
institutions.
We collected data from patients aged <18 years with thy-
roid nodules diagnosed by physical examination and thyroid
ultrasonography and with a histological diagnosis when sub-
mitted to surgery or a cytological diagnosis when submitted
to fine-needle aspiration biopsy (FNAB). Patients submitted
to FNAB but not to surgery because of benign cytology were
followed for at least 1 year, with clinical and echographic
evaluation every 6 months to further substantiate the benign
nature of the nodule. Inclusion criteria were: (1) largest
nodule diameter at least 1 cm and (2) serum TSH and free
thyroxine levels measured within the 3 months before
FNAB or surgery. The referring clinicians were asked to apply
the following exclusion criteria: (1) cases treated for any
other childhood cancer or exposed to radiation before the
diagnosis of thyroid nodules (n = 32); (2) cases with autoim-
mune thyroiditis confirmed by thyroid antibody detection or
an ultrasound pattern consistent with thyroiditis (inhomog-
enous and hypoechogenic) (n = 79); (3) cases in which levo-
thyroxine was administered before nodule diagnosis (n = 11);
(4) cases with hyperthyroidism (defined as TSH <0.4 mU/L)
or under methimazole/propylthiouracil treatment (n = 4);
(5) cases with hypothyroidism (defined as low serum free
thyroxine concentrations with a concomitant rise in TSH)
(n = 9); and (6) cases with a definite histological/cytological
diagnosis of thyroid abscess, medullary thyroid cancer, or a
rare thyroid histotype (eg, Hurtle-cell adenoma/carcinoma)
(n = 6).
Overall, 125 patients (105 females, 20males) were included
in this study. The cytological results yielded by FNAB were
classified according to accepted guidelines.23,24
Bodymass index (BMI) was defined as weight in kilograms
divided by the square of height in meters. Published Italian
standards for sex- and age-specific BMI percentiles were
used to classify patients aged 2-18 years as overweight
(85th-95th percentile) or obese (>95th percentile) and to
calculate the respective BMI SDS.25 Patients aged <2 years
with weight-for-length >95th percentile were classified as
obese.
Serum TSH concentration was measured by highly specific
chemiluminescent immunoassays (Roche Diagnostics,1466Manheim, Germany) in the laboratories of the various cen-
ters involved in the study, with intra-assay and interassay var-
iations <10%. TSH reference values were 0.40-4.40 mU/L in
all 9 laboratories.
Continuous variables are expressed as mean  SD (me-
dian, range). The Kolmogorov-Smirnov and Shapiro-Wilk
tests were used to assess the parametric or nonparametric dis-
tribution of the numerical variables. The Student t test and
Wilcoxon and Mann-Whitney tests were used to check
between-group differences in variables with a normal distri-
bution and in variables with a skewed distribution, respec-
tively. Pearson correlation coefficients were applied to
check univariate associations. The c2 test and Fisher exact
test were used to assess the distribution of cathegorical vari-
ables. Binary logistic regression analysis was used to evaluate
the independent influence of factors on the final diagnostic
outcome (benign vs malignant), including largest nodule
diameter, number of nodules (solitary nodules vs multinod-
ular thyroid disease), age, sex, and serum TSH concentration
at the time of FNAB.
Calculations were considered statistically significant at a P
value <.05. SPSS version 15.0 (IBM, Armonk, New York) was
used for all statistical analyses.Results
Of the 125 patients in our study cohort, 57 were submitted to
surgery based on an FNAB result indicative of malignant or
suspicious nodule or despite a benign cytology, clinical/echo-
graphic features suggestive of a malignancy (eg, palpable
lymph nodes, microcalcifications, intranodular blood flow,
ultrasonography-detected lymph node alterations, hypoe-
chogenicity, irregular margins). Cytology was benign in 86
patients (18 who underwent surgery with a final diagnosis
of goitrous nodule), malignant in 24 patients (all with histo-
logically confirmed papillary cancer), suspicious in 15 pa-
tients (all who underwent surgery, 2 with a final diagnosis
of follicular carcinoma, 6 with follicular adenoma, and 7
with benign goitrous nodule). Overall, 26 patients (20.8%)
were diagnosed withmalignant thyroid nodules based on his-
tology, 24 with papillary carcinoma and 2 with follicular car-
cinoma. The other 31 patients who underwent surgery
received a final diagnosis of benign thyroid nodules with his-
tology demonstrating goitrous nodule (n = 25) or follicular
adenoma (n = 6).
In 68 patients, surgery was not performed because the
nodule was considered benign. These patients (all with
benign FNAB findings) were followed for a mean of 2.3 
1.6 years (median, 2.8 years; range, 1.3-6.2 years) with clin-
ical, laboratory, and echographic evaluation every 6 months.
Over the follow-up period, no nodule developed suspicious
features for malignancy, and thus none of these patients
underwent surgery.
Concordance between cytology and histology was seen in
all the patients with benign and malignant cytology, and
considering the “suspicious” cytology results as malignant,Mussa et al
Table I. Patient characteristics
Characteristic Benign nodule (n = 99) Malignant nodule (n = 26) P value
Age at diagnosis, y, mean  SD (median, range) 11.4  3.3 (12.0, 0.7-17.9) 12.0  2.90 (12.0, 7.0-16.8) .417
Females/males, n 83/16 22/4 .989
Solitary/multinodular, n 71/28 22/4 .215
Largest nodule diameter at diagnosis, cm, mean  SD (median, range) 2.15  0.94 (2.05, 1.0-4.50) 2.42  0.92 (2.45, 1.00-4.10) .198
BMI SDS, mean  SD (range) 0.16  1.09 (1.88 to 3.36) 0.23  1.39 (1.67 to 2.83) .768
Age at FNAB, y, mean  SD (median, range) 11.9  3.45 (12.4, 0.7-17.9) 12.3  3.09 (12.4, 7.0-17.8) .552
Serum TSH concentration, mU/L, mean  SD (median, range) 1.64  0.99 (1.40, 0.40-6.00) 3.23  1.59 (2.85, 1.40-8.40) <.001
November 2013 ORIGINAL ARTICLESwe had 13 false-positive results (all “suspicious”), for an
overall sensitivity of 100%, specificity of 58%, and diagnostic
accuracy of 77%. Of the 125 patients, 26 had a differentiated
thyroid cancer and 99 had benign nodules (Table I).
Overall, themean serumTSH concentrationwas 2.01 1.30
mU/L (median, 1.60mU/L; range, 0.40-8.40mU/L).Thedistri-
bution of serum TSH concentrations followed a tight symmet-
rical Gaussian curve, peaking at a median value of 1.60 mU/L
(Figure 1). The mean serum TSH concentration was 3.23 
1.59 mU/L (median, 2.85 mU/L; range, 1.40-8.4 mU/L) in
the patients with thyroid cancer and 1.64  0.99 mU/L
(median, 1.40 mU/L; range, 0.41-6.00 mU/L) mU/L in those
with benign thyroid nodules, with a significant difference
between the 2 groups (P < .001). There was no sex-based
difference in the malignancy rate; malignancy was found in 4
of the 20 males (20.0%; 3 papillary cancers and 1 follicular
cancer) vs 22 of the 105 females (20.9%; 21 papillary and 1
follicular). Mean serum TSH concentration was significantly
lower in males compared with females (1.41  0.67 mU/L vs
2.13  1.37 mU/L; P < .001). Males and females showed no
significant differences in age at nodule diagnosis, age at
FNAB, BMI SDS, uninodular/multinodular ratio, or largest
nodule diameter. Moreover, there were no significant
differences between patients with solitary nodules and thoseFigure 1. Distribution of serum TSH concentrations in the study
thyroid nodules, and the dark-gray squares represent patients wi
distribution with a median serum TSH value of 1.60 mU/L. The box
75th percentiles represented by boxes, the median by a vertical l
median serum TSH concentration in benign nodules was 1.40 mU
all with serum TSH concentrations exceeding this value.
Serum Thyrotropin Concentration in Children with Isolated Thyrowith multinodular thyroid disease. Mean serum TSH
concentrations were comparable in obese (n = 5) and
overweight patients (n = 28) and patients with normal BMI
(1.84  1.12 mU/L vs 2.07  1.36 mU/L; P = .369). No
correlation was found between serum TSH concentration and
the largest nodule diameter, BMI SDS, patient age at nodule
diagnosis and at FNAB, or number of nodules, nor were any
correlations found when evaluating the patients with benign
nodules and those with malignant nodules separately.
Binary logistic regression analyses including sex, largest
nodule diameter, age at diagnosis, solitary ultrasound, unin-
odular or multinodular disease, and serum TSH concentra-
tion were performed to identify independent risk factors
predictive of thyroid malignancy. Significantly increased
ORs were found only for serum TSH concentration (P <
.001); none of the other factors was found to independently
predict the presence of malignancy (Table II).
The 125 patients were divided into 5 groups of 25 pa-
tients each based on serum TSH quintile: 0.40-1.00 mU/
L, 1.01-1.50 mU/L, 1.51-1.80 mU/L, 1.81-2.80 mU/L, and
>2.80 mU/L. The prevalence of malignancy increased
significantly (P < .001, c2 test) with increasing TSH con-
centration, with respective rates of 0%, 4%, 16%, 32%,
and 52% in the 5 quintiles (Figure 2). The OR ofcohort. The light-gray bars represent patients with benign
th thyroid cancer. The distribution roughly follows a normal
-and-whisker plot summarizes the distribution, with the 25th-
ine, the range by whiskers, and the outliers by squares. The
/L, and the cases with thyroid cancer were skewed rightward,
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Table II. Independent predictors of the diagnosis of
thyroid malignancy in binary logistic regression analysis
Variable aOR 95% CI P value
Sex 0.337 0.078-1.452 .144
Age at diagnosis 1.127 0.941-1.350 .194
Largest nodule diameter, cm 1.153 0.645-2.059 .631
Solitary vs multinodular 0.135 0.013-1.415 .095
Serum TSH 3.133 1.888-5.201 <.001
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thresholds of 1.50, 1.80, and 2.80 mU/L (Figure 2) and
the comparison of patients with a serum TSH above
versus below the median serum TSH concentration of the
cohort (1.6 mU/L), which resulted in an OR of 16.2.
Positive and negative predictive values were calculated for
the serum TSH thresholds of 1.60 and 2.80 mU/L and
found to be 36.4% and 96.6%, respectively, for the
former and 53.8% and 87.8% for the latter. The highest
diagnostic accuracy (87.1%) was found at the 2.80-mU/L
threshold.
All of the foregoing analyses (comparison of means be-
tween paired groups, binary logistic regression, and correla-
tions) were repeated including only the patients with
available histological results (ie, those submitted to surgery;
n = 57), yielding similar results. The results were also similar
when the 2 cases of differentiated thyroid cancer of follicularFigure 2. Prevalence of thyroid malignant nodules (dark gray)
over benign nodules (light gray) according to the serum TSH
concentration measured at diagnosis. The 125 patients were
divided into serum TSH quintiles in which the observed ma-
lignancy rate progressed significantly (0%, 4%, 16%, 32%,
and 52%, respectively, P < .001, c2 test). ORs for the 3 highest
thresholds are reported.
1468type, with serum TSH concentrations of 2.00 mU/L and 2.23
mU/L, were excluded from the analyses.
Discussion
Serum TSH determination at thyroid nodule presentation is
instrumental in the diagnostic evaluation of these nodules in
both adults and children.21-23 Recent studies of adults with
thyroid nodules have established a correlation between
serum TSH concentrations in the upper one-half of the
normal range and an increased likelihood of differentiated
thyroid carcinoma,13,14 suggesting that TSH concentration
can provide an additional clue to malignancy. We designed
the present study to evaluate this possibility in the pediatric
population, in which data are scanty.17
Consistent with previously published data, we observed a
striking right-skewed distribution of serum TSH concentra-
tions in children and adolescents with differentiated thyroid
cancer compared with those with benign thyroid nodules.
Although most laboratory reference ranges define the normal
range of serum TSH concentration as 0.4-4.4 mU/L, large
population studies have demonstrated a median TSH con-
centration of approximately 1.4-1.8 mU/L,26-28 suggesting
that a more realistic upper limit may be 2.5-3.0 mU/L. Given
the limitations of pediatric studies and the small size of our
cohort in the present study, our data are consistent with these
observations. The distribution of serum TSH concentrations
in the children and adolescents with benign nodules loosely
followed a Gaussian curve, peaking at approximately 1.50
mU/L, with some outliers in the right tail. Serum TSH con-
centrations of the patients with malignant nodules were
clearly scattered on the right part of the curve, falling mostly
in the right tail. In fact, all of the serum TSH values in the pa-
tients with thyroid carcinomas exceeded the median serum
TSH value of the patients with benign nodules. The mean
serum TSH concentration in the patients with thyroid carci-
nomas was almost double that in the patients with benign
nodules (3.2 mU/L vs 1.6 mU/L), as significant difference.
Dividing our cohort into quintiles based on serum TSH
concentration revealed an significantly increased prevalence
of thyroid cancer with increasing TSH concentration. Thy-
roid cancer was absent in the patients with a serum TSH value
of 0.40-1.0 mU/L, whereas its prevalence exceeded 50% in
those with a serum TSH value >2.8 mU/L. The odds of hav-
ing a malignant nodule increased progressively from the first
to fifth quintiles, with the patients with a serum TSH concen-
tration above the median value of our cohort (1.60 mU/L)
having an estimated 16-fold increase in cancer likelihood
compared with those with a serum TSH concentration below
this threshold. Finally, by multivariate analysis, we identified
serum TSH concentration as an independent predictor of
malignancy in our cohort, and determined that none of the
other covariates evaluated had an effect on final patient
outcomes.
Unlike Chiu et al17 and other investigators who evaluated
adults,14 we decided to exclude patients with autoimmune
thyroiditis and those previously treated with radiotherapyMussa et al
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etiology of thyroid nodules likely do not reflect those of the
general population, and thus we excluded these 2 conditions
to avoid possible confounding and bias. Moreover, hypothy-
roidism (with consequent increased serum TSH) is
commonly seen in both of these conditions.
Similarly, we decided to include only cases with papillary
or follicular thyroid cancer because these are the 2 malignant
histotypes most often seen in the pediatric population, and
also because papillary and follicular thyroid cancer are well
differentiated and thus expected to be highly TSH-
responsive compared with other, rarer histotypes. We also
checked for overweight/obesity as potential confounders
given the possible association with elevated serum TSH con-
centration,29 but found no correlation.
Our study has several limitations that should be acknowl-
edged. Given the study’s retrospective design and the fact that
thyroid nodules were mostly detected clinically, some small
and nonpalpable nodules possibly harboring carcinoma
might have been missed. Moreover, because thyroid nodules
and cancer is relatively rare in children compared with adults,
this was a multicenter study, and thus was potentially biased
by differences in the clinical management of patients fol-
lowed at the various centers. Furthermore, serum TSH deter-
mination and cytological/histological evaluation were not
performed in a centralized manner. Finally, in approximately
one-half of the patients, the benign nature of the nodules was
not confirmed histologically but rather was based on a benign
cytology plus a minimum of 1 year of follow-up. However,
FNAB is the recognized standard for evaluating thyroid nod-
ules in both adults and children, with proven high sensitivity
for detecting malignancies.30-33 Thus, we believe that consid-
ering those cases with a negative FNAB as benign is a reason-
able approach and is not likely to have a significant impact on
our results. Moreover, a separate statistical analysis including
only patients with histological results available yielded com-
parable results.
In conclusion, in medical practice, clinical, laboratory, and
echographic evaluations are used to determine the likelihood
of malignancy in pediatric patients with thyroid nodules and
to determine the need to refer for FNAB. Palpable lymph no-
des, microcalcifications, lymph node abnormalities, and
increased intranodular vascularization on ultrasonography
are suggestive of malignancy.21 Our results suggest that
serum TSH concentration has a role as a predictor of the like-
lihood of thyroid cancer in pediatric patients with thyroid
nodules and can be used in clinical practice to increase the
suspicion for a malignant etiology. Although serum TSH
fluctuations fall within the reference range in most patients
with thyroid nodules, those with malignant nodules are
more likely to have a serum TSH concentration in the
upper-normal range, and patients with a serum TSH value
>2.8 mU/L are at clearly increased risk for cancer. Thus,
serum TSH measurement should be added to the repertoire
of test and other variables used in the clinical setting to deter-
mine whether to submit patients with thyroid nodules to
further investigation by FNAB. Cytology remains the goldSerum Thyrotropin Concentration in Children with Isolated Thyrostandard for predicting malignancy and is more reliable
than any biochemical marker identified to date. n
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